FTC report finds 'pay for delay' patent settlements on the rise

Patent dispute settlements between brand-name and generic drug makers jumped sharply in the past year, the Federal Trade Commission has found in a new study, warning that such deals may be anticompetitive.

This article requires free registration

This article requires free registration to The National Law Journal. Please sign in or register to read the full text.